PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) - Vitolo, U.; Nowakowski, G. S.; Burke, J. M.; Fox, C. P.; Trneny, M.; Chiappella, A.; Waldron-Lynch, M.; Hadar, N.; Pachori, A.; Lenz, G.